ropathy, 16 HIV-associated neuropathy and 8 post herpetic neuralgia) with a mean age of 60.3(12.3) years and an even gender distribution were interviewed. Patient treatment experience ranged from anticonvulsants (73%), antidepressants (34%), opioids (25%), to topical medications (41%). Pain descriptors and treatment attributes were similar across the three NP groups. Pain relief was judged the most important treatment attribute, followed by ability to do activities. Sleep improvement was another important attribute. Activity limitations and QL were perceived as too broad and unspecific, and were split into 3 concepts each (self care, daily and physical activities; sleep, emotions, and social function). A 7-day recall period was introduced. The item stem and response options were made consistent, and a baseline and follow-up questionnaires were developed (except for the satisfaction items) to enable monitoring onset of treatment benefit and change over time. CONCLUSIONS: The content validity of the revised SAT was improved by the qualitative research, and NP treatment benefits are reflected in a more consistent fashion by the changes. Baseline and follow-up versions make assessments of change over time possible.
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PATIENT-REPORTED OUTCOME (PRO) INSTRUMENT FOR DETECTION OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH MULTIPLE MYELOMA (MM): THE FACT/GOG-NTX
Choi S 1 , Neuwirth R 1 , Cakana A 2 , San miguel JF 3 , Richardson PG 4 1 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, 2 Janssen-Cilag Pty Ltd, High Wycombe, UK, 3 Hospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain, 4 Dana-Farber Cancer Institute, Boston, MA, USA OBJECTIVES: Peripheral Neuropathy (PN) is a key side effect of several MM therapies, including bortezomib. PRO instruments, such as the FACT/GOG-Ntx (v4.0) 11-item 'Additional Concerns' scale, may be helpful for early identification of patients at risk or with subclinical evolving PN. This analysis evaluated its ability to predict PN after examining correlations between patient-reported FACT/GOG-Ntx and physician-documented clinical PN (NCI-CTCAE v3.0) using data from a phase 3 trial. METHODS: In the VISTA study, 682 untreated, transplant-ineligible MM patients (median age 71 years) received up to nine 6-week cycles of bortezomibmelphalan-prednisone (VMP) or MP, and completed FACT/GOG-Ntx v4.0 each cycle (day 1). Correlations between clinical PN and FACT/GOG-Ntx sensory subscale (items 1-4) were determined using Pearson correlation coefficients. A logistic regression model evaluated detection accuracy; receiver operating characteristic (ROC) curve analyses were conducted based on logistic regression results for prediction of clinical PN by FACT/GOG-Ntx sensory subscale at cycles 1-5. Area under ROC curve (AUC) is a measure of accuracy; AUC should be Ͼ.50 for an instrument to be useful. RESULTS: Pearson correlation coefficient was 0.43, 0.44, and 0.47 at cycles 3, 4, and 5, respectively, indicating some association between FACT/GOG-Ntx and clinical PN. Using ROC curve analysis for prediction of grade Ն1, Ն2, Ն3, and 4 PN, respectively, AUCs were: .52, .53, .57, and .63 at cycle 1; .63, .64, .63, and .85 at cycle 2; and .71, .75, .76, and .96 at cycle 3. At cycle 4, AUCs were .77, .79, and .75, and at cycle 5 were .78, .80, and .79 for grade Ն1, Ն2, and 3 PN, respectively. CONCLUSIONS: FACT/GOG-Ntx sensory subscale demonstrated substantial predictive utility for early detection of clinical PN. FACT/GOG-Ntx could be a useful PRO tool for early bortezomib-associated PN detection and management. Similar analyses of additional phase 2 (SUMMIT) and 3 (APEX) studies are planned.
PSY43 PATIENT PERSPECTIVES ON PERCEIVED VALUE OF TREATMENTS FOR MODERATE-TO-SEVERE PSORIASIS
Naim A 1 , Gollins JR 2 , Chen W 3 , Walls D 4 1 Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2 Delta Modelling Group, Mount Prospect, IL, USA, 3 DePaul University, Chicago, IL, USA, 4 BDJ Solutions, Medford, MA, USA OBJECTIVES: To examine patient perspectives on perceived value of medications used in moderate-to-severe psoriasis in the United States. METHODS: Online surveys and patient focus groups were conducted from a nationally representative psoriasis patient panel was conducted in April 2010. Respondents, aged Ն18 years old, were grouped as mild and moderate-to-severe psoriasis. Participants were asked to rate PsO severity based on palm rule where one palm is considered as covering 1% body surface area (BSA). Participants were also asked about time to diagnosis, treatment history, monthly out-of-pocket treatment costs, and value of treatments. RESULTS: Of the 1013 participants, 50% were male, and mean age was 49 years. Psoriasis disease severity was reported by 32% (nϭ321) as mild and 68% (nϭ692) as moderate-to-severe. Annual household income ranging from $25-75K was reported by 40% of participants. Over 70% had been diagnosed with psoriasis for Ն5years. Among those currently receiving prescription or over-the-counter psoriasis treatment (nϭ795), approximately one-third (mildϭ37%, moderate-se-vereϭ35%) reported very good/excellent value for their PsO treatment as compared to good (33% and 31%, respectively), fair (24%, 27%), and poor (6%, 8%). Patients receiving biologic or disease modifying anti-rheumatic drugs (DMARD) (47% and 52%, respectively) rated the value of their treatment as very good/excellent compared to other treatments, including light therapy. Those with out-of-pocket costs Ͻ$50 (mildϭ88%, moderate-severeϭ71%) were more likely to perceive their treatment is of very good/excellent value. CONCLUSIONS: The majority of participants in this survey suffered from long-standing moderate-to-severe psoriasis. The majority of participants, with the exception of those using biologics or DMARDs, perceived they weren't receiving good value for their psoriasis treatments. Participants with out-of-pocket medication costs less than $50/month perceived higher treatment value. 
PSY44 EXAMINING DISEASE AND PATIENT CHARACTERISTICS OF INDIVIDUALS WITH MODERATE-TO-SEVERE PSORIASIS IN A NATIONALLY REPRESENTATIVE POPULATION IN THE UNITED STATES
OBJECTIVES:
To examine characteristics of individuals with moderate-to-severe psoriasis in a US nationally representative population. METHODS: A nationally representative patient panel was surveyed in April 2010 to recruit adult (Ն18 years old) psoriasis patients of all severity levels. Participants were asked about severity of disease, affected locations, time to diagnosis, and treatment history. Participants rated disease severity based on "palm rule", where the palm of the hand was used to estimate 1% body surface area (BSA). RESULTS: A total of 1013 patients responded to the survey. Fifty percent were female, 32% (nϭ321) had mild and 68% (nϭ692) had moderate-to-severe psoriasis. Patient ages in years were distributed as follows: 30% Ͻ 40; 45% 40-59 and 25% Ͼ 60. Over 70% of both mild and moderatesevere severity patients were diagnosed Ն5 years ago. Among the moderate-tosevere group, the top three body locations affected were elbows and/or arms (70%), scalp (69%), and knees and/or legs (64%). 68% (nϭ471) characterized their psoriasis as moderate-to-severe at time of diagnosis and 78% (nϭ540) as moderate-to-severe before starting current treatment. Using the rule of palm, 70% reported 3-10% BSA at time of diagnosis, 72% before starting current treatment, and 45% currently. Prescription topical and other topical treatments were most commonly used (48.8% and 32.4% respectively), followed by over-the-counter (OTC) medications (25%), prescription oral (14.6%), 12.6% biologics, and phototherapy (7.4%). 20% of patients (nϭ139) reported as not currently treating their psoriasis. CONCLUSIONS: Psoriasis is a chronic condition affecting all age groups. The majority of patients are being diagnosed when the disease has progressed to moderate or severe stage. Individuals try various treatments to manage their psoriasis ranging from OTC medications to biologic treatments. Patient education and awareness programs, and shared-decision making aides may help with early diagnosis of psoriasis and enable optimal treatment. 
PSY45 EXAMINING PSORIASIS PATIENT PERSPECTIVES OF DISEASE AND TREATMENT: A NOVEL MULTI DISCRIMINATE APPROACH
OBJECTIVES:
To examine patient insights and perspectives among individuals with psoriasis using novel multi-discriminate analysis (MDA). METHODS: Patient focus groups and online surveys were conducted from a nationally representative psoriasis patient panel from 2Q-4Q2010. Participants were asked about treatments, impact on daily life, accessibility and affordability, and knowledge about psoriasis. Key audio excerpts from focus group transcripts were used for moment-to-moment analysis in an online survey of psoriasis patients Ն18 years old. Cluster analysis was used to segment patients into mutually exclusive patient groups based patient characteristics and preferences. MDA was performed to identify key points of divergence in perspective/opinion on the focus group dialogue. RESULTS: Of the 1013 respondents, 50% were female, 32% (nϭ321) had mild and 68% (nϭ692) had moderate-to-severe psoriasis. Patient ages in years were distributed as follows: 30% Ͻ 40; 45% 40-59 and 25% Ͼ 60. Patient preference for biologic treatments for A106 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
